论文部分内容阅读
血管紧张素转化酶抑制剂(ACEi)在临床上是作为心血管和肾脏疾病比较安全的治疗药物,其毒副作用较少。近年来发现癌症病人长期使用ACEi可以降低癌症发病率和死亡率。体内外实验表明,ACEi可以抑制肿瘤生长和转移,抑制肿瘤血管生成和细胞外基质降解等。ACEi抗癌作用的机制涉及干扰RAS系统(主要是抑制血管紧张素转化酶活性),以及抑制基质金属蛋白酶(MMP)活性等。几个大样本的流行病学研究发现,ACEi抗癌效果受到ACE的2个基因多态性A-240T和插入/缺失(I/D)影响。在含有低风险等位基因(A和I)的人群中ACEi抗癌效果比较明显,但这一现象在各个种族中有较大差异,并且受到绿茶饮用量等因素影响。既然ACEi已经在临床上广泛使用而无严重毒副作用,这为我们提供了癌症治疗和化学防护的新策略。
Angiotensin-converting enzyme inhibitors (ACEi) are clinically safe as cardiovascular and kidney therapies, with fewer toxic side effects. In recent years, found that long-term use of ACEi cancer patients can reduce cancer morbidity and mortality. In vitro and in vivo experiments show that ACEi can inhibit tumor growth and metastasis, inhibit tumor angiogenesis and extracellular matrix degradation. The mechanism by which ACEi has an anti-cancer effect involves interfering with the RAS system (mainly inhibiting angiotensin-converting enzyme activity) and inhibiting matrix metalloproteinase (MMP) activity. Epidemiological studies in several large samples have found that ACEi’s anticancer effect is affected by two ACE polymorphisms, A-240T and insertion / deletion (I / D). The anticancer effect of ACEi is more obvious in people with low-risk alleles (A and I), but this phenomenon is quite different in all races and is influenced by factors such as green tea consumption. Since ACEi is already widely used clinically without serious side effects, it offers us a new strategy for cancer treatment and chemoprevention.